Back to Search Start Over

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.

Authors :
Hellwig, Kerstin
Geissbuehler, Yvonne
Sabidó, Meritxell
Popescu, Catrinel
Adamo, Alessandra
Klinger, Joachim
Ornoy, Asher
Huppke, Peter
the European Interferon-beta Pregnancy Study Group
Akbaba, Metin
Borghesi, Gustavo
Bugge, Joerg-Peter
Detering, Elke
Köfüncü, Evra
Luenzmann, Claudia
Mueller, Bettina
Olivar, Axel
Suzart-Woischnik, Kiliana
Wicklein, Eva-Maria
Beynon, Vanessa
Source :
Journal of Neurology. Jun2020, Vol. 267 Issue 6, p1715-1723. 9p.
Publication Year :
2020

Abstract

Background: Family planning is an important consideration for women with multiple sclerosis (MS), who are often diagnosed during their reproductive years. Currently, limited data are available on pregnancy outcomes in patients exposed to interferon-beta (IFN-beta) before or during pregnancy. Here, we present the cumulative pregnancy exposure data and prevalence of pregnancy and infant outcomes in IFN-beta-exposed pregnant women with MS from the European IFN-beta Pregnancy Registry. Methods: Using spontaneous and solicited reports, the registry collected data from 26 countries of the European Economic Area, consisting of information on women with MS identifying themselves to one of the Marketing Authorisation Holders (Bayer, Biogen, Merck KGaA, and Novartis) or healthcare professionals as pregnant and exposed to IFN-beta during pregnancy or within 1 month before conception. The outcomes collected by the registry included ectopic pregnancies, spontaneous abortions, elective terminations, live, and stillbirths with or without congenital anomalies. The prevalence of pregnancy outcomes was put in context with those reported in the general population. Results: Between 2009 and 2017, the registry collected 948 pregnancy reports with a known pregnancy outcome. Overall, 82.0% (777/948) of pregnancies resulted in live birth without congenital anomaly. When comparing IFN-beta-exposed pregnancies with the general population, the prevalence of spontaneous abortions (10.7% vs. 10–21%) and congenital anomalies in live births (2.1% vs. 2.1–4.1%) were found to be within reported ranges. Conclusions: The data gathered from these pregnancy cases suggest no evidence that IFN-beta exposure before conception and/or during pregnancy adversely increases the rate of congenital anomalies or spontaneous abortions. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03405354
Volume :
267
Issue :
6
Database :
Academic Search Index
Journal :
Journal of Neurology
Publication Type :
Academic Journal
Accession number :
143759315
Full Text :
https://doi.org/10.1007/s00415-020-09762-y